Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Apr 26, 2024 1:49pm
184 Views
Post# 36009880

Another week almost over, recap

Another week almost over, recap

Hello all;
Yet another week is almost over.
Acutually 3 more trading days & a new month.
Did anything important or significant happen this week?
Regarding my comments, I have extream myopia. Being an Onc chat board, I only see or care about Onc progress, developments and outlooks.
in that regard? How is Onc doing ? This week?
On the heals of announcing the FDA meeting request for phase 3 MBc details, they announced an upcoming presentation at ASCO, 
Date being May 23, before the abstract details we be public.
Two features, one being TIL expansion in pancreatic, Brest & colon cancer.
The other being a further update on Pancreatic cancer.
Not to be forgotten, they. Did announce goid reults from the colon leg of the gobblet trials.
I would not be surprised if they added the colon cancer to an additional phase 3 enrolment.
Shareholder value? Absolutely. 
Things need to happen. The science is slow. However many avenues point towards Onc being successful. 
They won't be showcasing bad outcomes at ASCO.
Safe weekend all.
 

 

<< Previous
Bullboard Posts
Next >>